Do the numbers hold clues to what lies ahead for the stock?Kaskela Law LLC Announces Investigation of Unum Therapeutics Inc. and Encourages Long-Term Investors to Contact the Firm - UMRXUnum Therapeutics Inc.
Get short term trading ideas from the MarketBeat Idea Engine. Learn everything you need to know about successful options trading with this three-part video course.Looking for new stock ideas?
© 2020 Market data provided is at least 10-minutes delayed and hosted by MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. The average … Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Unum Therapeutics Inc. - UMRX - Stock Price Today - Zacks UMRX is …
Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.
The high price target for UMRX is $4.00 and the low price target for UMRX is $3.00. The 1 year target estimate that I am hoping for is $1.50.
Export data to Excel for your own analysis. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Log in to see them here or sign up to get started.Create a list of the investments you want to track.Visit a quote page and your recently viewed tickers will be displayed here.Unum Therapeutics Inc. (UMRX) closed the most recent trading day at $2.74, moving +1.86% from the previous trading session.Dynavax (DVAX) inks a deal with Mount Sinai to develop a universal influenza vaccine candidate using its CpG 1018 adjuvant. Lack of a marketed product is a concern.Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder.
Announces Acquisition of Kiq LLCINVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Unum Therapeutics Inc. for Potential Breach of Fiduciary Duty ClaimsINVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Unum Therapeutics Inc. for Potential Breach of Fiduciary Duty ClaimsUnum Therapeutics Reports First Quarter Financial Results and Provides Corporate UpdatesUnum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates
Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Unum Therapeutics Inc. (NASDAQ:UMRX) trade information Wall Street analysts have a consensus price target for the stock at $4, which means that the shares’ value could jump 48.7% from current levels.
The development is funded under a contract win from NIAID.Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 17thNabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. (Highest and lowest possible predicted price in a 14 day period) Detailed Trend Components of the Unum Therapeutics Inc Stock Price Forecast & Prognosis Have Watchlists?
MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
By using this site you agree to the 4 analysts have issued 1 year price objectives for Unum Therapeutics' stock.
Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.
Trump suggests freezing evictions and payroll-tax collection through executive orders Based on 1 analyst offering 12 month price targets for Unum Therapeutics in the last 3 months. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. UMRX price target in 14 days: 5.182 USD* upside and 2.264 USD* downside.
View which stocks are hot on social media with MarketBeat's trending stocks report.Identify stocks that meet your criteria using seven unique stock screeners. The lighter blue line represents the stock's consensus price target.